17-Dimethylaminoethylamino-17-Demethoxygeldanamycin (17-DMAG) in Treating Patients With Metastatic Solid Tumors or Tumors That Cannot Be Removed By Surgery

Unspecified Adult Solid Tumor, Protocol Specific Clinical Trial

Official title:
A Cancer Research UK Phase I Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of 17-Dimethylaminoethyl-amino-17-Demethoxygeldanamycin (17-DMAG) Given as a Once Weekly Infusion in Patients With Advanced Solid Tumors

Status Active, not recruiting

Clinical Trial Summary

RATIONALE: Drugs used in chemotherapy, such as 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.

PURPOSE: This phase I trial is studying the side effects and best dose of 17-DMAG in treating patients with metastatic solid tumors or tumors that cannot be removed by surgery.

Clinical Trial Description

OBJECTIVES:

Primary

- Determine the maximum tolerated dose, dose-limiting toxicity, and recommended phase II dose of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in patients with unresectable or metastatic solid tumors.

- Determine the feasibility, safety, and toxicity profile of this drug in these patients.

Secondary

- Determine the clinical pharmacokinetic profile of this drug in these patients.

- Determine tumor response in patients treated with this drug.

- Determine the biologically effective dose.

OUTLINE: This is an open-label, non-randomized, dose-escalation, multicenter study.

Patients receive 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) IV over 1 hour on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Cohorts of 3-6 patients receive escalating doses of 17-DMAG until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. An additional 10 patients are treated at the MTD.

After completion of study treatment, patients are followed for 28 days.

PROJECTED ACCRUAL: Approximately 25-35 patients will be accrued for this study within 12-18 months. ;

Study Design

Allocation: Non-Randomized, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Unspecified Adult Solid Tumor, Protocol Specific

Clinical Trial Details

NCT number	NCT00248521
Study type	Interventional
Source	National Cancer Institute (NCI)
Contact
Status	Active, not recruiting
Phase	Phase 1
Start date	October 2005

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01828775` - Palliative Care Intervention in Improving Quality of Life, Psychological Distress, and Communication in Patients With Solid Tumors Receiving Treatment	N/A
Terminated	`NCT01642342` - Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors	Phase 1
Completed	`NCT00002950` - Topotecan Plus Sargramostim in Treating Patients With Advanced Cancer	Phase 1/Phase 2
Completed	`NCT01705548` - Hypofractionated Stereotactic Radiosurgery in Treating Patients With Large Brain Metastasis	N/A
Completed	`NCT02146222` - VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Docetaxel in Treating Patients With Solid Tumors	Phase 1
Terminated	`NCT01602627` - Hsp90 Inhibitor AUY922 in Treating Older Patients With Advanced Solid Malignancies	Phase 1
Completed	`NCT01191216` - 1-Methyl-D-Tryptophan and Docetaxel in Treating Patients With Metastatic Solid Tumors	Phase 1
Recruiting	`NCT00992303` - Collecting Tissue Samples From Patients With Cancer Undergoing Radiation Therapy and Healthy Participants
Recruiting	`NCT01137825` - Registry of Older Patients With Cancer
Completed	`NCT00924651` - Exercise in Lessening Fatigue Caused by Cancer in Patients Undergoing Chemotherapy	Phase 3
Completed	`NCT00949949` - Everolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable Solid Tumors Refractory to Standard Therapy	Phase 1
Suspended	`NCT00935090` - 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer	N/A
Withdrawn	`NCT00937417` - S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors	Phase 1
Active, not recruiting	`NCT00710632` - Screening to Predict Weight Loss in Patients With Cancer	N/A
Completed	`NCT00544596` - R-(-)-Gossypol Acetic Acid, Cisplatin, and Etoposide in Treating Patients With Advanced Solid Tumors or Extensive Stage Small Cell Lung Cancer	Phase 1
Completed	`NCT00573690` - Sorafenib Combined With Cisplatin and Etoposide or Carboplatin and Pemetrexed in Treating Patients With Metastatic Solid Tumors	Phase 1
Active, not recruiting	`NCT00436735` - Nelfinavir in Treating Patients With Metastatic, Refractory, or Recurrent Solid Tumors	Phase 1
Completed	`NCT00352443` - S0528 Lapatinib and Everolimus in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma	Phase 1
Completed	`NCT00126620` - Sorafenib and Erlotinib in Treating Patients With Metastatic or Unresectable Solid Tumors	Phase 1
Completed	`NCT00255658` - Sorafenib and Temsirolimus in Treating Patients With Unresectable or Metastatic Solid Tumors	Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.